Business context and reporting period
Important issuer mismatch: The supplied filing is Bioptix, Inc.’s Form 10-Q for the quarter ended March 31, 2017—not a filing by Riot Platforms, Inc. This summary reflects the filing as provided.
Bioptix reported a minimal continuing business and, effective January 14, 2017, adopted a plan to exit its BiOptix Diagnostics, Inc. (BDI) business. It expected to dispose of BDI assets and operations during 2017 through asset sales and/or intellectual-property licensing. Continuing revenue was primarily amortization of an animal-health license fee.
Financial results and position
| Metric | Three months ended March 31, 2017 | Comparable 2016 period / balance |
|---|---|---|
| Revenue | $24,175 continuing license-fee revenue; BDI discontinued-operation sales were $13,000 | $24,175 continuing revenue |
| Operating loss, continuing operations | $1.03 million | $1.38 million |
| Net income (loss) | $(4.35) million, including $3.35 million loss from discontinued operations | $560,000 income |
| Cash used in operating activities | $1.66 million total: $1.00 million continuing and $662,000 discontinued | $1.90 million |
| Cash and cash equivalents | $11.98 million at March 31, 2017 | $5.53 million at December 31, 2016 |
| Working capital | $11.47 million | — |
| Total liabilities / equity | $1.92 million / $11.41 million at March 31, 2017 | $2.12 million / $14.92 million at December 31, 2016 |
| Debt | $56,158 of current installment obligations; no mortgage debt | $139,611 of current obligations at December 31, 2016 |
Operating expenses were $1.05 million, including $1.03 million of selling, general and administrative expense and $18,000 of research and development expense. No meaningful continuing gross margin is reported. The quarter’s $2.70 million BDI impairment included write-downs of inventory, equipment, identifiable intangible assets and goodwill.
Cash increased by $6.45 million, principally reflecting $7.51 million of proceeds from sales of short-term investments and $706,000 of net proceeds from an equity issuance, partially offset by operating cash use and debt repayments.
Material changes versus the prior comparable period
- Net results changed from $560,000 income to a $4.35 million loss. The 2016 result included a $1.92 million gain on sale of property and equipment; there was no comparable gain in 2017.
- Research and development expense fell approximately 95%, to $18,000, as APPY 1 development and manufacturing activities were wound down.
- BDI was reclassified as discontinued operations, with a $3.35 million quarterly loss, including a $2.70 million impairment charge.
- Cash rose from $5.53 million at year-end, while total assets fell from $17.04 million to $13.32 million, largely reflecting the BDI exit and impairment.
Outlook, risks and unusual items
- Management expected near-term operating losses, potentially significant, due to BDI exit costs and ongoing public-company and administrative expenses. It said available working capital was expected to cover estimated cash needs through May 2018 (also described as at least a year and a day from the filing); this outlook was subject to uncertainty and possible strategic transactions.
- Management was exploring strategic alternatives and financing, including monetizing, partnering or licensing assets such as its appendicitis product portfolio, and continuing cost controls. It cautioned that additional financing might not be available on acceptable terms, or at all.
- March 2017 financing included $1.00 million gross proceeds from a common-stock offering, with another $1.25 million in escrow, and $4.75 million of convertible-note proceeds also in escrow pending release conditions outside the company’s control. The escrowed amounts were not available cash at quarter-end.
- BDI’s office and laboratory lease required future payments, but after quarter-end the company reached an agreement to terminate it, prepay rent through July 31, 2017, and surrender a $37,000 deposit.
- On April 10, 2017, Nasdaq notified the company that its audit committee did not meet the requirement for at least three independent directors. The notice had no immediate effect on listing or trading.
- Bioptix disclosed recurring losses and negative operating cash flows. It reported no legal proceedings believed likely to have a material adverse effect, and no material changes to the risk factors in its 2016 Form 10-K.
Most important facts for investors to verify
- Confirm the intended issuer: this filing identifies Bioptix, Inc., not Riot Platforms, Inc.
- Check whether the $1.25 million common-stock proceeds and $4.75 million convertible-note proceeds held in escrow were subsequently released, and review their resulting dilution, conversion and warrant terms.
- Verify actual BDI asset-sale or licensing proceeds, final exit costs, and whether management’s cash-runway estimate was achieved.
- Review subsequent filings for developments in the Nasdaq audit-committee deficiency and any strategic transaction or financing.
- Assess continuing cash burn and the sustainability of the small license-fee revenue stream.